IL-35+Breg/Il-35 Effect on T Cell Immune in Patients With CHB
NCT ID: NCT03734783
Last Updated: 2019-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2017-07-01
2019-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studies of Immune Responses in Patients With Chronic Hepatitis B
NCT00155155
T-cell Dysfunction in Chronic HBV Infection
NCT05099458
NK Cell Deregulation in HBV Patients
NCT03761875
Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients
NCT04356404
Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment
NCT02348502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Here the investigators intended to investigate the regulating role and the mechanism of CD19+ IL-35+ cells on host T cell immune during chronic HBV infection by using in vitro cell sorting, B cell differentiation induction, Transwell cell co-culture system and other methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients
HBsAg positive more than 6 months
No interventions assigned to this group
health control
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 17\<age\<70
* Can read, understand and sign patients informed consent
Exclusion Criteria
* Have malignancy
* Have uncontrollable extra-hepatic disease
17 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
LiangXS
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Liu Y, Luo Y, Zhu T, Jiang M, Tian Z, Tang G, Liang X. Regulatory B Cells Dysregulated T Cell Function in an IL-35-Dependent Way in Patients With Chronic Hepatitis B. Front Immunol. 2021 Apr 12;12:653198. doi: 10.3389/fimmu.2021.653198. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16ZR1400400
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.